France has confirmed it will dramatically reduce its financial
contribution to the global fight against HIV/AIDS, a decision that is
already drawing fierce criticism from public health organizations and
political leaders. The cuts will push France from the world’s
second-largest contributor to fifth place, marking a sharp reversal from
the leadership role it once claimed in global health efforts.
The
French government confirmed that between 2026 and 2028 it plans to
contribute €860 million combined to the Global Fund and Unitaid, two of
the world’s main organizations financing the fight against HIV/AIDS,
tuberculosis, and malaria.
That figure represents a reduction of
more than half of France’s previous commitment. During the last funding
cycle from 2023 to 2025, France pledged €1.6 billion to the Global Fund
to Fight AIDS, Tuberculosis and Malaria alone, plus an additional €255
million to Unitaid.
The decision confirms earlier reports revealed
in February and effectively ends hopes that Paris might reverse course
ahead of the upcoming One Health Summit, which President Emmanuel Macron
is scheduled to open in Lyon.
Officials say the decision is driven by France’s deteriorating public finances.
According
to the Ministry of Foreign Affairs, the government is attempting to
reduce the national deficit to 5% of GDP by 2026, forcing significant
spending cuts across multiple sectors.
“Public finances are
currently under considerable pressure,” the ministry said in a
statement. Despite the cuts, it insisted that global health remains a
priority area of France’s international solidarity policy.
Critics, however, say the numbers tell a different story.
Nine HIV/AIDS organizations condemned the move in a joint statement,
calling it a dangerous retreat from global health leadership.
“France is abandoning millions of people,” said Camille Spire, president of the French HIV advocacy group AIDES.
“This
is the largest reduction among all G7 countries,” added Florence Thune,
head of Sidaction. “France is effectively deserting the global fight
against pandemics.”
The cuts will have immediate geopolitical
implications as well. France’s reduced commitment now places it behind
the United States, Germany, and the United Kingdom, and even behind the
philanthropic funding of the Bill & Melinda Gates Foundation, which
pledged €788 million.
The decision is also facing criticism inside France’s parliament.
On
February 3, the National Assembly of France unanimously passed a
resolution calling on the government to maintain strong financial
support in the global fight against HIV/AIDS.
The measure, introduced by Socialist MP Arthur Delaporte, passed with all 135 votes in favor, though it is not legally binding.
Delaporte
urged the government to reconsider the cuts, warning that France risks
abandoning its long-standing international role in global health.
“The government is choosing to follow the same unfortunate path as Donald Trump,” he said.
His
comment refers to the recent reduction in U.S. funding for global HIV
programs. Since Trump returned to the White House, the United States —
historically the world’s largest contributor — has reportedly reduced
its global HIV/AIDS funding from $6 billion to $4.6 billion.
Public health experts say the symbolism of France’s decision may be as damaging as the financial impact.
For
years, France positioned itself as one of the key champions of global
HIV/AIDS programs. That reputation was cemented in 2019 when France
hosted a major replenishment conference for the Global Fund to Fight
AIDS, Tuberculosis and Malaria in Lyon.
At the time, President Emmanuel Macron delivered a passionate speech urging world leaders to intensify their efforts.
“The goal of ending the epidemic by 2030 is achievable,” he said then. “But only if we live up to our responsibilities today.”
Many activists now say those words ring hollow.
Advocacy
groups warn that the combination of reduced funding from both the
United States and France could derail global efforts to eliminate
HIV/AIDS as a public health threat by 2030.
“Who can still believe the epidemic will end by 2030?” asked the French advocacy group Actions Traitements.
“What once seemed achievable just a few years ago is quickly becoming impossible.”
The
Global Fund to Fight AIDS, Tuberculosis and Malaria had hoped to raise
$18 billion for its next three-year funding cycle, but current pledges
suggest the total may fall below $13 billion — a shortfall that could
directly impact treatment, prevention programs, and lifesaving
medication in many parts of the world.
For critics, the concern is
simple: when major donors pull back, the consequences are measured not
just in budgets — but in lives.